Researchers develop Lassa fever treatment effective eight days after infection

September 5, 2017
Credit: University of Texas Medical Branch at Galveston

A collaborative team of scientists, led by a group at The University of Texas Medical Branch at Galveston, have successfully protected nonhuman primates against one of the most deadly viruses in the world, Lassa fever, eight days after they became infected. The findings are now available in Nature Medicine.

The virus, for which there are no approved vaccines or treatments, infects hundreds of thousands of people every year and is estimated to kill approximately 34 percent of those infected, according to the Centers for Disease Control and Prevention. Also, military and science experts say that the virus could be used as a biological terror weapon.

"In this study, we tested a combination of three by giving them to beginning up to eight days following exposure to a lethal amount of Lassa virus," said UTMB's Thomas Geisbert, a professor in the Department of Microbiology and Immunology. "We found that the treatments were well-tolerated and provided 100 percent protection from Lassa fever. Without treatment, the animals show evidence of the virus in their bodies by day four after exposure."

Monoclonal antibodies are widely used for treating cancers and autoimmune diseases and more than 45 different types are approved by the U.S. Food and Drug Administration and European Medicines Agency.

"The fact that the treatment was able to rescue 100 percent of the animals more than a week after infection with Lassa virus suggests that this therapy may benefit patients with Lassa fever in West Africa, who often arrive at the clinic at a late stage of disease," said Robert Garry, a professor in the department of microbiology and immunology at Tulane. "We are accelerating further development so that this promising treatment can be introduced into clinics in West Africa and deployed as a deterrent against the use of Lassa virus as a bioweapon."

Recently, travelers on commercial airlines have imported Lassa fever into Europe and the U.S., highlighting the potential for spread of the disease. The disease is classified as a Category A pathogen - an organism that poses the highest risk to national security and public health - by several U.S. government agencies because of the concern for deliberate misuse.

Explore further: Lassa fever kills two in Lagos, 100 others on watch: hospital

More information: Chad E Mire et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever, Nature Medicine (2017). DOI: 10.1038/nm.4396

Related Stories

Lassa fever kills two in Lagos, 100 others on watch: hospital

August 9, 2017
Two people in Lagos have died and a hundred medical workers have been placed under observation after a flare-up of Lassa fever, a cousin of the deadly Ebola virus, officials said Wednesday.

Antiviral favipiravir successfully treats Lassa virus in guinea pigs

October 13, 2015
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National ...

Monoclonal antibody cures Marburg infection in monkeys

April 5, 2017
An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The ...

Nine people suspected dead of Lassa fever in Benin

February 2, 2016
As the world ramps up its fight against the Zika virus, West Africa is battling to contain a growing outbreak of Lassa fever with nine people in Benin reported dead, a health official told AFP Tuesday.

Studies of US Lassa fever patient offer clues about immune response, viral persistence

June 22, 2017
When an American nurse working in West Africa became ill with Lassa fever and was evacuated to the U.S. for treatment in 2016, it provided a rare opportunity. With the consent of the patient, researchers were able to closely ...

Two dead from Ebola-like Lassa fever in Benin: officials

November 21, 2014
Two people have died in Benin from the Ebola-like virus Lassa fever, the country's government and a World Health Organization (WHO) official said on Friday.

Recommended for you

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

Research team unlocks secrets of Ebola

November 16, 2017
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin-Madison has ...

Study raises possibility of naturally acquired immunity against Zika virus

November 16, 2017
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.

A structural clue to attacking malaria's 'Achilles heel'

November 16, 2017
Researchers from The Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite though investigation of antibodies generated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.